-
Recent Posts
- Late-Life Depression: Prevalence and Treatment Considerations (JGCR)
- Babylon Health Applies Artificial Intelligence to Improving Integration of Care and Population Health in Wolverhampton (HTN / RWT / BMJ / Lancet / NHS England)
- Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)
- Dementia-Related Hospital Admissions (BBC News / Alzheimer’s Society)
- NHS Demands Action to Reduce Betting-Related Ill Health (BBC News / NHS England / Respublica)
Archives
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Alzheimer’s Research UK Drug Discovery Institute
Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)
Summary Animal research, involving mice, has indicated promising results for the potential of two re-purposed drugs in helping to slow or halt the progression of a number of neurodegenerative brain diseases, including dementia. “The best known drug of the pair … Continue reading →
Posted in Animal Studies, BBC News, For Researchers (mostly), In the News, National, NHS Digital (Previously NHS Choices), Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Abnormal Prion Protein, Alzheimer's Disease, Alzheimer's Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Autoimmune Attacks, Autoimmune Cell Defences, BBC Health News, Behind the Headlines, Brain (Journal), Centre for Analytical Bioscience: University of Nottingham, CJD, Creutzfeldt-Jakob Disease, Creuzfeldt Jacob Disease (CJD), Department of Clinical Neurosciences: University of Cambridge, Dibenzoylmethane, Dibenzoylmethane (DBM): Potential Anti-Cancer Drug, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr David Dexter: Parkinson's UK, Dr Doug Brown: Director of Research and Development at Alzheimer's Society, Drug Discovery Programmes, eIF2a-P-Mediated Translational Repression (Pathway of Neurodegeneration), Frontotemporal Dementia (FTD), Huntingtin Protein, Huntington’s Disease, α-Synuclein, α-Synuclein Aggregation, Lentivirally Mediated RNA Interference (RNAi), Medical Research Council (MRC), Medical Research Council (UK), Medical Research Council Toxicology Unit: University of Leicester, Medical Research Council’s (MRC) Toxicology Unit, Microscopic Worms, Misfolded Prion Protein (PrP), Misfolded Proteins, Motor Neurone Disease (MND), MRC Toxicology Unit: University of Leicester, MRC: Medical Research Council, Multiple Sclerosis, National Institute for Neurological Disorders and Stroke, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Loss, Neuroprotection, Parkinson's, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prion Diseases, Prion Protein (PrP(C)), Prion-Infected Mice, Prof. Giovanna Mallucci, Professor Giovanna Mallucci: Associate Drector of UK Dementia Research Institute, Protein Misfolding, Rare Prion Diseases, Repurposing of Drugs, Synucleinopathy, Tau, Tau Protein, Tauopathy, Translational Research, Transmissible Spongiform Encephalopathies, Trazodone, Trazodone Hydrochloride (Antidepressant), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Unfolded Protein Response (UPR), University of Cambridge, University of Leicester, University of Nottingham, Worms: C. elegans
|
Leave a comment
Repurposing of Existing Drugs to Prevent Dementia? (BBC News / Science Advances /Alzheimer’s Research UK)
Summary A number of drugs, already approved as safe for the treatment of other conditions, and which could help protect against Alzheimer’s Disease, are said to have been detected and short-listed for further investigation. Full Text Link Reference Alzheimer’s preventative … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Animal Studies, BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Ab42 Fibril Formation, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta Protein, Amyloid Cascade Hypothesis, Amyloid Hypothesis, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β Protein, Anti-Amyloid Therapies, ARUK: Alzheimer’s Research UK, ß-amyloid, BBC Health News, Behind the Headlines, Beta-Amyloid, Bexarotene (Elevated Triglycerides), Bexarotene (Targretin), Center for Molecular Protein Science: Lund University, Cleveland Clinic Lou Ruvo Center for Brain Health, Collaborative Drug Discovery Programmes, Conversion to Dementia From Prodromal Disease, Critical Appraisals, Department of Biochemistry and Structural Biology: Lund University, Department of Chemistry: University of Cambridge, Department of Psychology: University of Nevada, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, European Research Institute for the Biology of Aging (Groningen), Fibrillar Deposits (Alzheimer's Disease), Fibrils, β-Amyloid 1-42 (Aβ42), Lund University (Sweden), Microscopic Worms, Netherlands, Neurofibrillary Tangles (NFTs), Neurological Research, Neurostatin (Hypothetical Construct), Off-Label Drug Repurposing Trials, Off-Licence Drugs, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prodromal Alzheimer's Disease, Protein Aggregation, Repurposing of Drugs, RXR Agonists, Science Advances (Journal), Statins for the Brain (Hypothetical Construct), Sweden, University Medical Centre Groningen, University of Cambridge, University of Groningen, University of Nevada, USA, Worms: C. elegans
|
Leave a comment
UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has announced the launch of the Drug Discovery Alliance, a £30 million network of research centres working collaboratively on research to discover potential cures, or at least disease modifying treatments, for Alzheimer’s Disease and other forms … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, For Researchers (mostly), In the News, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Alzheimer’s Research UK Drug Discovery Institute, Alzheimer’s Research UK’s Drug Discovery Alliance, Big Pharma, Cambridge Biomedical Campus, Cambridge Drug Discovery Institute, Cambridge University, Clinical Research Networks, Collaborative Drug Discovery Programmes, Commissioning Research, Crowd-Sourced Information, Crowdsourcing, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Dr Laura Phipps: Alzheimer’s Research UK, Drug Discovery Alliance, Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, Genetic Research, Genetic Triggers, Global Action Against Dementia, Global Clinical Development Fund, Global Context, Global Dementia Legacy Event, Global Leadership, Global Outlook, Gurdon Institute: University of Cambridge, Innovation in Genetics, International Collaborations, International Organisations, International Programmes, Knowledge Networks, Knowledge Translation, Medical Research, MIT Sloan School of Management: Model for Public-Private Partnerships in Funding Research, Multidisciplinary Research Teams, Networks, Networks and Alliances, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Oxford Drug Discovery Institute, Oxford University, Parallel Discovery of Alzheimer’s Therapeutics (MIT Sloan and University of California Model), Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmacological Research, Philanthropic Funding, Philanthropy, Prof. David Rubinsztein: Lead Academic Scientist at Cambridge Drug Discovery Institute, Prof. Giampietro Schiavo: Co-Lead Academic Scientist at UCL Drug Discovery Institute, Prof; Simon Lovestone: Co-Lead Academic Scientists at Oxford Drug Discovery Institute, Research Commitment, Research Consortia, Research Culture, Research Mapping, Research Networks, Research Programmes, Scientific Management Board of the Drug Discovery Institute, Stem Cell Research, Translational Research, UCL Drug Discovery Institute, University College London (UCL), University of Cambridge, University of Oxford
|
Leave a comment
Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has launched the Global Clinical Trials Fund (GCTF) to help finance trials which aim to translate discoveries in the lab into clinical treatments for the 830,000 people living with dementia in the UK. The GCTF aims … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Clinical Trials, Clinical Trials (Phase I Through Phase III), Clinical Trials and Treatment Assessments, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Commissioning Research, Dementia Consortium, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, GCTF: Global Clinical Trials Fund, Global Action Against Dementia, Global Clinical Trials Fund (GCTF), International Collaborations, International Organisations, International Programmes, Intervention Trials, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Non-Drug Intervention Trials, Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Research Commitment, Research Consortia, Research Culture, Research Programmes, Technology Transfer, Translational Research
|
Leave a comment
Annual Progress Report(s) on Prime Minister’s Dementia Challenge (Department of Health / Dementia Challenge)
Summary The three Dementia Challenge Champion Groups have written brief reports detailing their progress during the past year. These reports feature in a letter to the Prime Minister (see below), which also reiterates achievements since the Prime Minister’s Dementia Challenge … Continue reading →
Posted in Acute Hospitals, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Health Education England (HEE), In the News, Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, Patient Care Pathway, Person-Centred Care, Personalisation, Quick Insights, Standards, UK, Universal Interest
|
Tagged 6Cs Live!, 6Cs Live! Communications Hub, 6Cs Live! Website, Accuracy of Dementia Prevalence Data, Alborada Trust, Alzheimer's Research UK, Alzheimer’s Research UK Drug Discovery Institute, Alzheimer’s Society’s Drug Discovery Programme, Awareness Raising, Best Practice for Dementia Care, Better Care Fund and Integration Pioneers, Black and Minority Ethnic (BME), Black and Minority Ethnic Older People, BME Communities, BME: Black and Minority Ethnic, Breakthrough Challenge for Dementia, British Standards Institution (BSI), British Standards Institution (BSI): Code of Practice for Dementia Friendly Communities, Building Dementia Friendly Communities, Care England, Caregiver Support, Carer Support, Carers Call to Action, Carers Included: A Guide to Best Practice in Acute Mental Health Care, Centres of Excellence in Neurodegeneration Initiative (CoEN), Centres of Excellence in Neurodegenerative disease (CoEN) Pathfinder Grants, Challenge on Dementia (David Cameron), Clinical Research Networks, Code of Practice for Dementia Friendly Communities, Curriculum for Dementia Education (CfDE), Data Sharing, Dementia and Homecare, Dementia Assessment and Referral Data, Dementia Awareness, Dementia Care and Support Compact, Dementia Case Records Interactive Search System, Dementia Challenge, Dementia Challenge Champion Groups, Dementia Choices (NHS Choices), Dementia Commissioning for Quality and Innovation (CQUIN), Dementia Commissioning for Quality and Innovation (CQUIN) Reward, Dementia Diagnosis, Dementia Directed Enhanced Service (DES), Dementia Friendly Awards, Dementia Friendly Churches Sermon Pack, Dementia Friendly Communities Champion Group, Dementia Friendly Communities Programme, Dementia Friendly Communities Recognition Process, Dementia Friendly Communities Recognition Process: Barnsley, Dementia Friendly Communities Recognition Process: Bexhill, Dementia Friendly Communities Recognition Process: Bourne, Dementia Friendly Communities Recognition Process: Bracknell Forest, Dementia Friendly Communities Recognition Process: Bradford, Dementia Friendly Communities Recognition Process: Bury, Dementia Friendly Communities Recognition Process: Camelford, Dementia Friendly Communities Recognition Process: Corbridge, Dementia Friendly Communities Recognition Process: Coventry, Dementia Friendly Communities Recognition Process: Crawley, Dementia Friendly Communities Recognition Process: Deal, Dementia Friendly Communities Recognition Process: Debenham, Dementia Friendly Communities Recognition Process: Doncaster, Dementia Friendly Communities Recognition Process: Falmouth, Dementia Friendly Communities Recognition Process: Gedling, Dementia Friendly Communities Recognition Process: Hampshire, Dementia Friendly Communities Recognition Process: Kent, Dementia Friendly Communities Recognition Process: Lancaster Morecambe and District, Dementia Friendly Communities Recognition Process: Leeds, Dementia Friendly Communities Recognition Process: Liverpool, Dementia Friendly Communities Recognition Process: London Borough of Richmond, Dementia Friendly Communities Recognition Process: Luton, Dementia Friendly Communities Recognition Process: Malpas, Dementia Friendly Communities Recognition Process: Manchester, Dementia Friendly Communities Recognition Process: Marple (Stockport), Dementia Friendly Communities Recognition Process: Newbury, Dementia Friendly Communities Recognition Process: North and Northeast Lincolnshire, Dementia Friendly Communities Recognition Process: Peterborough, Dementia Friendly Communities Recognition Process: Plymouth, Dementia Friendly Communities Recognition Process: Poole, Dementia Friendly Communities Recognition Process: Portsmouth, Dementia Friendly Communities Recognition Process: Salford, Dementia Friendly Communities Recognition Process: Sandwell, Dementia Friendly Communities Recognition Process: Sheffield, Dementia Friendly Communities Recognition Process: Stockon, Dementia Friendly Communities Recognition Process: Surrey, Dementia Friendly Communities Recognition Process: Tavistock, Dementia Friendly Communities Recognition Process: The Parishes of Wembury Brixton Yealmpton Newton and Noss and Holbeton, Dementia Friendly Communities Recognition Process: Thurrock, Dementia Friendly Communities Recognition Process: Tring, Dementia Friendly Communities Recognition Process: Wakefield, Dementia Friendly Communities Recognition Process: Warwickshire, Dementia Friendly Communities Recognition Process: Wimborne, Dementia Friendly Communities Recognition Process: Windsor and Maidenhead, Dementia Friendly Communities Recognition Process: Wokingham, Dementia Friendly Communities Recognition Process: Wolverhampton, Dementia Friendly Communities Recognition Process: Worthing, Dementia Friendly Communities Recognition Process: York, Dementia Friendly Communities Recognition Process: Yorkshire, Dementia Friendly Financial Services Charter, Dementia Friendly Technologies, Dementia Friends, Dementia Friends Campaign, Dementia Health and Care Champion Group, Dementia Resource Suite for Schools, Dementia Roadmap Web-Based Tool, Dementia Technology Charter, Dementia-Friendly Businesses, Dementia-Friendly Cities, Dementia-Friendly Communities, Dementia-Friendly Environments, Dementia-Friendly Hospitals, Dementia-Friendly Industries, Dementia-Friendly Neighbourhoods, Dementia-Friendly Organisations, Dementia-Friendly Sectors, Dementia-Friendly Shops, Dementia-Friendly Towns, Dementia-Friendly Yorkshire, DementiaChoices Website, Dementias and Neurodegenerative Diseases Research Network (DeNDRoN), DeNDRoN: Dementias and Neurodegenerative Diseases Research Network, Dennis Gillings: Former World Dementia Envoy, Department of Health’s Post Diagnosis Working Group, Diagnosis Rates, Diagnosis Rates Ambition (UK), Directed Enhanced Service (DES), Doctoral Training Centres, Drug Discovery Institute, Drug Discovery Programme, Drug Discovery Programme (Alzheimer's Society), Early Intervention Dementia Service, Early Intervention Dementia Service in Worcestershire, Economic and Social Research Council (ESRC), Enabling Research in Care Homes (ENRICH), Engaging Businesses in Dementia Friends, ENRICH: Enabling Research in Care Homes, ENRICH: Toolkit for Care Home Research, ESRC: Economic and Social Research Council, EU Joint Programme in Neurodegenerative Disease (JPND), EU Joint Programme: Neurodegenerative Disease Research (JPND), Faith Groups, Financial Services Dementia Charter, G8 Dementia Summit, G8 Dementia Summit: Global Action Against Dementia, Global Action Against Dementia, Greenwich Advanced Dementia Service (GADS), Health and Care Champion Group, HEE: Health Education England, HEE’s Investment in Dementia Education and Training, Higher Education for Dementia Network (HEDN), IAPT: Improving Access to Psychological Therapies, Identification and Validation of Therapeutic Targets, Improving Access to Psychological Therapies (IAPT) Programme, Innovation Challenge Prize for Dementia, International Programmes, International Research, Janssen Healthcare Innovation, Join Dementia Research National Service, Join Dementia Research: Recruitment Onto Dementia Studies, JPND Research Projects, JPND: Joint Programme on Neurodegenerative Disease Research, Knowledge Translation, Laboratory of Molecular Biology (LMB) Neuroscience Division, Lifestyle Factors, Lifestyle Risk Factors, Liviability, Liviability: Dementia Friendly Churches Sermon Pack, Living Well After Diagnosis, Local Dementia Action Alliances, Local Dementia Action Alliances in England, London School of Economics, MAGDR: Ministerial Advisory Group on Dementia Research, Medical Research Council (MRC), Memory First, Memory First (Staffordshire), Memory Services National Accreditation Programme, Memory Services National Accreditation Programme (MSNAP), Ministerial Advisory Group on Dementia Research (MAGDR), MRC UK Dementias Research Platform (UKDP), MSNAP: Memory Services National Accreditation Programme, National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs), National Council for Palliative Care, National Institute for Health Research (NIHR), National Minimum Data Set for Social Care, National Minimum Data Set for Social Care: Skills for Care, National Strategic Clinical Network (SCN) for Mental Health, NHS Innovation Challenge Prize for Dementia, NIHR Biomedical Research Centres, NIHR Biomedical Research Units, NIHR Dementia Translational Research Centre, Nursing and Care Quality Forum, Participation in Research, Patient Involvement in Research, Personal Social Services Survey of Adult Carers in England, Personalised Care Planning, Personalised Care Plans, Post-Diagnosis Support, Post-Diagnostic Dementia Support, Post-Diagnostic Support, Power of Attorney, Prevention of Dementia, Prime Minister's Challenge on Dementia, Prime Minister’s Challenge on Dementia: Annual Reports (2014), Prime Minister’s Challenge on Dementia: Progress in Year Two, Prime Minister’s Dementia Challenge, Professor Martin Rossor: NIHR National Director for Dementia Research, Professor Patrick Maxwell, Public Awareness, Public Health England, Public Involvement in Research, Qualification and Credit Framework, Reducing Delays in Dementia Diagnosis, Referral and Assessment, Research Spending on Dementia, Responding to Dementia: Inclusion for All, Skills for Care, Stem Cell Research Centre, Strategic Clinical Network: Mental Health; Dementia and Neurological Conditions, Strategic Clinical Networks, Strategic Clinical Networks (SCNs), Support for Carers, Support for Carers of People with Dementia, Task and Finish Groups, Translational Research, UK Dementias Research Platform, UK Home Care Association, Voluntary Sector
|
Leave a comment
Drug Discovery Institute (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has announced proposals to create Europe’s first Drug Discovery Institute for neurodegenerative diseases including dementia. The aim of the multi-million pound Drug Discovery Institute will be to accelerate progress towards effective treatments for Alzheimer’s disease and other dementias. … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, For Researchers (mostly), International, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Commissioning Research, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Dr Simon Ridley, Drug Discovery Institute, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, International Collaborations, International Organisations, International Programmes, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Pharmacological Research, Research Commitment, Research Consortia, Research Culture, Research Mapping, Research Programmes, Scientific Management Board of the Drug Discovery Institute, Translational Research
|
Leave a comment
